IGM Historical Cash Flow
| IGMS Stock | USD 10.79 0.75 7.47% |
Analysis of IGM Biosciences cash flow over time is an excellent tool to project IGM Biosciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 48.9 M or Begin Period Cash Flow of 84.6 M as it is a great indicator of IGM Biosciences ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining IGM Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether IGM Biosciences is a good buy for the upcoming year.
IGM |
About IGM Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in IGM balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which IGM's non-liquid assets can be easily converted into cash.
IGM Biosciences Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by IGM Biosciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of IGM Biosciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from IGM Biosciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into IGM Biosciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IGM Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For more information on how to buy IGM Stock please use our How to Invest in IGM Biosciences guide.At this time, IGM Biosciences' Investments are comparatively stable compared to the past year. Stock Based Compensation is likely to gain to about 48.9 M in 2024, despite the fact that Change In Cash is likely to grow to (8.4 M).
IGM Biosciences cash flow statement Correlations
Click cells to compare fundamentals
IGM Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
IGM Biosciences cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | 17.3M | (324K) | (1.7M) | (1.6M) | (1.4M) | (1.3M) | |
| Investments | (203.2M) | 57.7M | 28.1M | (225.6M) | 64.2M | 67.4M | |
| Change In Cash | 33.9M | 205.2M | (107.0M) | (12.1M) | (8.8M) | (8.4M) | |
| Stock Based Compensation | 1.0M | 8.5M | 25.9M | 44.7M | 46.5M | 48.9M | |
| Free Cash Flow | (47.5M) | (84.8M) | (137.6M) | (16.1M) | (204.6M) | (194.4M) | |
| Change In Working Capital | (5.0M) | 2.0M | 6.4M | 155.2M | (6.7M) | (6.4M) | |
| Begin Period Cash Flow | 2.0M | 35.9M | 241.1M | 134.0M | 121.9M | 84.6M | |
| Total Cashflows From Investing Activities | (203.2M) | 57.7M | 14.8M | (225.6M) | (203.1M) | (192.9M) | |
| Other Cashflows From Financing Activities | 282.3M | (910K) | 2.5M | 1.4M | 3.0M | 2.9M | |
| Depreciation | 597K | 1.0M | 4.5M | 6.1M | 8.3M | 8.7M | |
| Capital Expenditures | 2.3M | 17.5M | 13.2M | 10.2M | 12.4M | 8.9M | |
| Total Cash From Operating Activities | (45.1M) | (67.3M) | (124.3M) | (5.9M) | (192.2M) | (182.6M) | |
| Change To Operating Activities | (7.0M) | (188K) | 5.8M | 9.2M | 10.6M | 11.2M | |
| Net Income | (43.1M) | (81.4M) | (165.2M) | (221.1M) | (246.4M) | (234.1M) | |
| Total Cash From Financing Activities | 282.3M | 214.8M | 2.5M | 219.4M | 115.1M | 135.8M | |
| End Period Cash Flow | 35.9M | 241.1M | 134.0M | 121.9M | 113.1M | 101.9M | |
| Change To Netincome | 2.4M | 11.0M | 25.7M | 54.0M | 62.1M | 65.2M | |
| Change To Liabilities | 2.0M | 2.2M | 13.2M | 145.9M | 167.8M | 176.2M | |
| Other Non Cash Items | 1.7M | 2.6M | 3.2M | 9.3M | 6.1M | 4.2M | |
| Issuance Of Capital Stock | 269.2M | 216.2M | 0.0 | 218.0M | 113.6M | 152.9M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.